AIM ImmunoTech Inc

(NYSE MKT:AIM)

Latest On AIM ImmunoTech Inc (AIM):

Date/Time Type Description Signal Details
2023-05-17 00:16 ESTNewsAIM ImmunoTech Inc. (AIM) Q1 2023 Earnings Call TranscriptN/A
2023-05-15 20:39 ESTNewsAIM ImmunoTech GAAP EPS of -$0.08N/A
2023-05-12 20:16 ESTNewsAlimera Sciences Q1 2023 Earnings PreviewN/A
2023-04-03 17:09 ESTNewsAIM ImmunoTech GAAP EPS of -$0.40, revenue of $0.14MN/A
2023-04-03 17:08 ESTNewsAIM ImmunoTech Inc. (AIM) Q4 2022 Earnings Call TranscriptN/A
2023-03-08 22:04 ESTNewsAIM Immunotech reports new analysis of Ampligen as a potential therapy against Ebola virus diseaseN/A
2023-01-17 17:17 ESTNewsAIM ImmunoTech gains on research deal for lead assetN/A
2022-11-15 14:54 ESTNewsAIM ImmunoTech GAAP EPS of -$0.13 misses by $0.01N/A
2022-11-02 13:08 ESTNewsAIM ImmunoTech soars on FDA orphan drug tag for Ampligen to treat Ebola virus diseaseN/A
2022-10-31 14:05 ESTNewsAIM ImmunoTech says court denies activist request on board nomineesN/A
2022-08-19 10:33 ESTNewsAIM ImmunoTech commences phase 2 study of Ampligen for treatment of pancreatic cancerN/A
2022-07-28 20:18 ESTNewsAIM ImmunoTech to further study long COVID therapy after early positive dataN/A
2022-06-13 19:23 ESTNewsAIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatmentN/A
2022-05-18 21:23 ESTNewsAIM working on new drug application for Ampligen mid-stage study to treat long COVIDN/A
2022-04-21 14:48 ESTNewsAIM ImmunoTech gains on data for Ampligen/checkpoint inhibitor combo in cancerN/A
2022-04-11 17:05 ESTNewsAIM ImmunoTech gains on positive data for Ampligen from two cancer trialsN/A
2022-04-01 02:21 ESTNewsAIM ImmunoTech GAAP EPS of -$0.04N/A
2022-03-17 01:00 ESTNewsAIM Immunotech stock soars 25% as FDA lifts hold, paving way for pancreatic cancer studyN/A
2022-03-09 19:35 ESTNewsAIM ImmunoTech's Ampligen helps improve survival of pancreatic cancer patients in studyN/A
2022-03-07 15:24 ESTNewsAIM Immunotech announces sale of New Brunswick, New Jersey facilityN/A
2022-03-04 00:53 ESTNewsAIM ImmunoTech appoints Dickey IV as CFON/A
2022-01-24 16:38 ESTNewsAIM ImmunoTech reports positive data from phase1/2 trial in ovarian cancerN/A
2021-11-16 15:41 ESTNewsAIM ImmunoTech EPS in-lineN/A
2021-10-20 02:12 ESTNewsAIM ImmunoTech submits IND and Fast Track application for Ampligen in pancreatic cancerN/A
2021-10-07 03:58 ESTNewsAIM ImmunoTech to explore Ampligen as intranasal COVID therapy after positive safety dataN/A
2021-09-30 08:45 ESTNewsAIM ImmunoTech inks clinical trial agreement for Phase 2a Human Challenge Trial of AmpligenN/A
2021-09-28 11:24 ESTNewsAIM ImmunoTech submits FDA Pre-IND application for mid-stage Ampligen COVID-19 trialsN/A
2021-09-27 12:13 ESTNewsAIM ImmunoTech files provisional patent application for AmpligenN/A
2021-09-21 11:20 ESTNewsAIM Immunotech reports positive FDA response for Ampligen trialN/A
2021-09-08 23:41 ESTNewsAIM Immunotech submits pre-IND application for mid-stage Ampligen COVID-19 studyN/A
2021-08-25 12:27 ESTNewsAIM ImmunoTech files provisional patent application for use of Ampligen in PCCDN/A
2021-08-18 04:26 ESTNewsAIM ImmunoTech EPS misses by $0.04N/A
2021-07-20 18:38 ESTNewsAIM ImmunoTech completes dosing in Cohort 3 of early-stage Ampligen trialN/A
2021-07-20 18:37 ESTNewsAIM ImmunoTech extends prior research agreement to develop Ampligen as new inhalation therapyN/A
2021-07-20 18:24 ESTNewsAIM Immunotech completes all treatments in early-stage ampligen studyN/A
2021-07-20 18:13 ESTNewsAIM Immunotech to test Ampligen in mid-stage intranasal antiviral therapy trialN/A
2021-04-27 11:42 ESTNewsAIM ImmunoTech advances Phase 1 Ampligen study in COVID-19; reports no serious adverse eventsN/A
2021-04-07 10:22 ESTNewsAIM ImmunoTech advances in Phase 1 study for COVID-19 therapyN/A
2021-03-31 16:12 ESTNewsAIM ImmunoTech EPS misses by $0.02, misses on revenueN/A
2021-03-16 18:56 ESTNewsAIM ImmunoTech (AIM) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - SlideshowN/A
2021-03-08 17:10 ESTNewsAIM Immunotech starts dosing in early-stage intranasal ampligen studyN/A
2021-02-24 21:46 ESTNewsAIM Immunotech shares jump after subsidiary nabs Orphan Medicinal Product status from ECN/A
2021-01-29 13:23 ESTNewsAIM ImmunoTech in pact with a university for proposed Ampligen studyin COVID-19N/A
2021-01-06 16:52 ESTNewsDosing underway in AIM Immunotech's "long hauler" part of ampligen COVID-19 trialN/A
2020-12-24 18:37 ESTNewsAIM ImmunoTech's Ampligen trial in COVID-19 'long Haulers' moves forwardN/A
2020-12-21 22:12 ESTNewsAIM ImmunoTech' Ampligen an Orphan Drug in U.S. for the treatment of pancreatic cancerN/A
2020-12-13 03:06 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:04 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 11:06 ESTAnalyst RatingThe Analyst Target Price has increased from $6.25 to $6.33.Buy
2020-11-25 17:08 ESTNewsDosing underway in AIM ImmunoTech's Ampligen in combo trial in COVID-19 patients with cancerN/A

About AIM ImmunoTech Inc (AIM):

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

AIM Quotes by TradingView

See Advanced Chart

General

  • Name AIM ImmunoTech Inc
  • Symbol AIM
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 24
  • Last Split Factor1:44
  • Last Split Date2019-06-11
  • Fiscal Year EndJanuary
  • IPO Date1996-07-12
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryAerospace & Defense
  • Web URLhttp://www.aimimmuno.com
View More

Valuation

  • Trailing PE 1.35
  • Price/Sales (Trailing 12 Mt.) 315.13
  • Price/Book (Most Recent Quarter) 1.52
  • Enterprise Value Revenue 323.93
View More

Financials

  • Most Recent Quarter 2020-07-31
  • Operating Margin -7609%
  • Return on Assets -19%
  • Return on Equity -31%
  • Revenue 171000
  • Earnings Per Share -$7.70
  • Revenue Per Share $0.01
  • Gross Profit -753000
  • Quarterly Earnings Growth -41%
View More

Highlights

  • Market Capitalization 98.46 million
  • EBITDA -11030000
  • PE Ratio -0.75
  • Analyst Target Price $6.33
  • Book Value Per Share $2.14
View More

Share Statistics

  • Shares Outstanding 40.69 million
  • Shares Float 40.21 million
  • % Held by Insiders 147%
  • % Held by Institutions 6.68%
  • Shares Short 1.7 million
  • Shares Short Prior Month 1.9 million
  • Short Ratio 0.31
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta -0.81
  • 52 Week High $4.3
  • 52 Week Low $1.6
  • 50 Day Moving Average 2.34
  • 200 Day Moving Average 2.1
View More

Dividends

  • Dividend Date 2019-06-11
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AIM ImmunoTech Inc (AIM) Dividend Calendar:

AIM's last dividend payment was made to shareholders on June 11, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AIM ImmunoTech Inc (AIM) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-10-312020-11-12-$0.08-$0.083.96%
2020-07-312020-08-14$N/A-$0.12-$0.11-6.55%
2020-04-302020-05-14$N/A-$0.22-$0.10-131.58%
2020-01-312020-03-30$45000-$0.13-$0.3764.86%
2019-10-312019-11-14$50000-$1.13-$0.97-16.49%
2019-07-312019-08-14$61000-$1.07-$1.7037.06%
2019-04-302019-05-15$29000-$2.77-$2.20-25.8%
2019-01-312019-04-01$N/A-$1.40-$3.0854.57%
2018-10-312018-11-14$240000-$3.08-$2.64-16.67%
2018-07-312018-08-14$38000-$2.38
2018-04-302018-05-15-$3.29
2018-01-312018-03-30-$2.67
2017-10-312017-11-14-$1.83
2017-07-312017-08-14-$3.53
2017-04-302017-05-15-$4.90
2017-01-312017-03-31-$2.13
2016-10-312016-11-14-$5.77
2016-07-312016-08-15-$2.77
2016-04-302016-05-16-$4.62
2016-01-312016-03-29-$6.69
2015-10-312015-11-17-$8.14
2015-07-312015-08-13-$10.83
2015-04-302015-05-13-$8.51
2015-01-312015-03-20-$11.53
2014-10-312014-11-07-$10.56-$15.8433.33%
2014-07-312014-08-08-$15.84-$15.840%
2014-04-302014-05-09-$11.46
2014-01-312014-03-14-$10.56-$15.8433.33%
2013-10-312013-11-11-$16.20
2013-07-312013-08-09-$13.53
2013-04-302013-05-08$7.11 million-$11.43
2013-01-312013-03-18$8.92 million-$15.84
2012-10-312012-11-02$7.27 million-$25.38
2012-07-312012-08-06$7.47 million-$11.65
2012-04-302012-05-07$7.36 million-$8.97
2012-01-312012-03-27$9.16 million-$12.14
2011-10-312011-11-09$7.32 million-$10.68
2011-07-312011-08-05$6.42 million-$10.56-$15.8433.33%
2011-04-302011-05-06$6.71 million-$21.12-$15.84-33.33%
2011-01-312011-03-29$8.83 million-$10.56-$15.8433.33%
2010-10-312010-11-08$7.05 million-$10.56-$15.8433.33%
2010-07-312010-08-06$6.81 million-$15.84-$15.31-3.46%
2010-04-302010-05-07$6.93 million-$15.84-$15.31-3.46%
2010-01-312010-03-15$6.71 million-$10.56-$10.03-5.28%
2009-10-312009-11-09$7.54 million-$10.56-$15.3131.03%
2009-07-312009-08-10$8.11 million-$21.12-$16.37-29.02%
2009-04-302009-05-12$8.77 million-$20.42
2009-01-312009-03-16$4.92 million-$19.93
2008-10-312008-11-10$2.92 million-$24.07
2008-07-312008-08-12$5.96 million-$19.98
2008-04-302008-05-13$6.65 million-$22.62
2008-01-312008-03-18$5.87 million-$26.40
2007-10-312007-11-08$7.43 million-$41.46
2007-07-312007-08-09$5.29 million-$28.71
2007-04-302007-05-16$6.83 million-$36.96-$42.2412.5%
2007-01-312007-03-19$7.26 million-$36.96-$31.68-16.67%
2006-10-312006-11-07$7.92 million-$32.13
2006-07-312006-08-14$7.6 million-$41.90
2006-04-302006-06-30$8.48 million-$53.67
2006-01-312006-03-16$7.75 million-$36.96
2005-10-312005-11-10$8.96 million-$29.71
2005-07-312005-08-10$8.98 million-$40.06
2005-04-302005-05-11$9.08 million-$37.87
2005-01-312005-03-16$7.55 million-$26.40
2004-10-312004-11-10$8.14 million-$78.61
2004-07-312004-08-11$7.94 million-$71.68
2004-04-302004-05-14$7.1 million-$104.41
2004-01-312004-03-15$6.65 million-$58.08
2003-10-312003-11-18$7.97 million-$77.73
2003-07-312003-08-20$7.75 million-$58.11
2003-04-302003-05-20$8.74 million-$26.36
2002-10-312002-12-31$7 million-$23.22
2002-07-312002-09-30$5.97 million-$31.11
2002-04-302002-06-30$6.02 million-$43.34
2002-01-312002-03-31$6.48 million-$24.50
2001-10-312001-12-31$6.99 million-$35.53
2001-07-312001-09-30$7.43 million-$37.10
2001-04-302001-06-30$6.52 million-$41.09
2001-01-312001-03-31$6.85 million-$43.71
2000-10-312000-12-31$5.71 million-$44.31
2000-07-312000-09-30$5.63 million-$36.95
2000-04-302000-06-30$6.48 million-$37.46
2000-01-312000-03-31$6.28 million-$36.85
1999-10-311999-12-31-$36.96
1999-07-311999-09-30-$37.69
1999-04-301999-06-30-$58.04
1999-01-311999-03-31-$58.28
1998-07-311998-09-30-$38.58
1998-04-301998-06-30-$38.99
1998-01-311998-03-31-$37.13

AIM ImmunoTech Inc (AIM) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AIM ImmunoTech Inc (AIM) Chart:

AIM ImmunoTech Inc (AIM) News:

Below you will find a list of latest news for AIM ImmunoTech Inc (AIM) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AIM ImmunoTech Inc (AIM) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest AIM Trades:

Date Shares Price
Jun 13, 2022 7:53 PM EST100$0.846
Jun 13, 2022 7:53 PM EST200$0.84
Jun 13, 2022 7:53 PM EST10$0.8555
Jun 13, 2022 7:54 PM EST100$0.8555
Jun 13, 2022 7:56 PM EST1$0.8225

AIM ImmunoTech Inc (AIM) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220011683/0001493152-20-011683-index.htm
2019-09-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/946644/000000000019013535/0000000000-19-013535-index.htm
2019-09-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/946644/000000000019013891/0000000000-19-013891-index.htm
2019-09-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/946644/000000000019013949/0000000000-19-013949-index.htm
2019-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000001/0001191434-19-000001-index.htm
2019-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000002/0001191434-19-000002-index.htm
2019-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000003/0001191434-19-000003-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000004/0001191434-19-000004-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000005/0001191434-19-000005-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000006/0001191434-19-000006-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000007/0001191434-19-000007-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000008/0001191434-19-000008-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000009/0001191434-19-000009-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000010/0001191434-19-000010-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000011/0001191434-19-000011-index.htm
2019-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000012/0001191434-19-000012-index.htm
2019-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000013/0001191434-19-000013-index.htm
2019-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000014/0001191434-19-000014-index.htm
2019-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000015/0001191434-19-000015-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000016/0001191434-19-000016-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000017/0001191434-19-000017-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000018/0001191434-19-000018-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000019/0001191434-19-000019-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000020/0001191434-19-000020-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143419000021/0001191434-19-000021-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000119143420000001/0001191434-20-000001-index.htm
2019-09-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/946644/000119312519257987/0001193125-19-257987-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/946644/000119312520038382/0001193125-20-038382-index.htm
2020-01-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/946644/000139382520000010/0001393825-20-000010-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000011/0001450324-19-000011-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000012/0001450324-19-000012-index.htm
2019-10-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000013/0001450324-19-000013-index.htm
2019-10-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000014/0001450324-19-000014-index.htm
2019-10-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000015/0001450324-19-000015-index.htm
2019-10-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000016/0001450324-19-000016-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000017/0001450324-19-000017-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000018/0001450324-19-000018-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000019/0001450324-19-000019-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000020/0001450324-19-000020-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000021/0001450324-19-000021-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000022/0001450324-19-000022-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000023/0001450324-19-000023-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000024/0001450324-19-000024-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000025/0001450324-19-000025-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000026/0001450324-19-000026-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000027/0001450324-19-000027-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000028/0001450324-19-000028-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000029/0001450324-19-000029-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032419000030/0001450324-19-000030-index.htm
2020-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000001/0001450324-20-000001-index.htm
2020-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000002/0001450324-20-000002-index.htm
2020-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000003/0001450324-20-000003-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000004/0001450324-20-000004-index.htm
2020-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000005/0001450324-20-000005-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000145032420000006/0001450324-20-000006-index.htm
2019-04-09SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/946644/000149315219005045/0001493152-19-005045-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/946644/000149315219005800/0001493152-19-005800-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219006271/0001493152-19-006271-index.htm
2019-05-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/946644/000149315219006314/0001493152-19-006314-index.htm
2019-05-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/946644/000149315219006316/0001493152-19-006316-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315219007385/0001493152-19-007385-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219008454/0001493152-19-008454-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219008701/0001493152-19-008701-index.htm
2019-06-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/946644/000149315219009371/0001493152-19-009371-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219009853/0001493152-19-009853-index.htm
2019-06-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/946644/000149315219009885/0001493152-19-009885-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219010919/0001493152-19-010919-index.htm
2019-07-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/946644/000149315219010927/0001493152-19-010927-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315219012572/0001493152-19-012572-index.htm
2019-08-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/946644/000149315219013142/0001493152-19-013142-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219013294/0001493152-19-013294-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219013386/0001493152-19-013386-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/946644/000149315219013821/0001493152-19-013821-index.htm
2019-09-06S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/946644/000149315219013823/0001493152-19-013823-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219013838/0001493152-19-013838-index.htm
2019-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219014139/0001493152-19-014139-index.htm
2019-09-24S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/946644/000149315219014454/0001493152-19-014454-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219014466/0001493152-19-014466-index.htm
2019-09-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/946644/000149315219014475/0001493152-19-014475-index.htm
2019-09-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/946644/000149315219014476/0001493152-19-014476-index.htm
2019-09-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/946644/000149315219014477/0001493152-19-014477-index.htm
2019-09-24S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/946644/000149315219014486/0001493152-19-014486-index.htm
2019-09-25S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/946644/000149315219014528/0001493152-19-014528-index.htm
2019-09-26424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/946644/000149315219014625/0001493152-19-014625-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219014689/0001493152-19-014689-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219015112/0001493152-19-015112-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219015596/0001493152-19-015596-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315219017506/0001493152-19-017506-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219018705/0001493152-19-018705-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315219019007/0001493152-19-019007-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220001904/0001493152-20-001904-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220002633/0001493152-20-002633-index.htm
2020-03-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/946644/000149315220003284/0001493152-20-003284-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220003568/0001493152-20-003568-index.htm
2020-03-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/946644/000149315220003675/0001493152-20-003675-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220004743/0001493152-20-004743-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220004768/0001493152-20-004768-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/946644/000149315220005290/0001493152-20-005290-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220005912/0001493152-20-005912-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220006554/0001493152-20-006554-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220007168/0001493152-20-007168-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315220008572/0001493152-20-008572-index.htm
2020-05-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315220008595/0001493152-20-008595-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220010677/0001493152-20-010677-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220011151/0001493152-20-011151-index.htm
2020-06-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/946644/000149315220011189/0001493152-20-011189-index.htm
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220011683/0001493152-20-011683-index.htm
2020-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220012600/0001493152-20-012600-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220012885/0001493152-20-012885-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220014436/0001493152-20-014436-index.htm
2020-08-03S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/946644/000149315220014500/0001493152-20-014500-index.htm
2020-08-11DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/946644/000149315220015281/0001493152-20-015281-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/0001493152-20-015932-index.htm
2020-08-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/946644/000149315220016213/0001493152-20-016213-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220016968/0001493152-20-016968-index.htm
2020-08-318-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220016985/0001493152-20-016985-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220018915/0001493152-20-018915-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220018981/0001493152-20-018981-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/946644/000149315220019098/0001493152-20-019098-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000158370119000006/0001583701-19-000006-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000158370119000007/0001583701-19-000007-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000002/0001613377-19-000002-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000003/0001613377-19-000003-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000004/0001613377-19-000004-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000005/0001613377-19-000005-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000006/0001613377-19-000006-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000161337719000007/0001613377-19-000007-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000001/0001702626-19-000001-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000002/0001702626-19-000002-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000003/0001702626-19-000003-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000004/0001702626-19-000004-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000005/0001702626-19-000005-index.htm
2019-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000006/0001702626-19-000006-index.htm
2019-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000007/0001702626-19-000007-index.htm
2019-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262619000008/0001702626-19-000008-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000170262620000001/0001702626-20-000001-index.htm
2019-09-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/946644/000178890819000002/0001788908-19-000002-index.htm
2019-09-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/946644/999999999519002175/9999999995-19-002175-index.htm

AIM ImmunoTech Inc (AIM) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AIM ImmunoTech Inc (AIM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 147%
Institutional Ownership: 668%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-15THOMAS K. EQUELSExec.Vice Chairman/CEO/Pres.Buy16,622.000.477,812.34108,758.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000018/0001450324-19-000018-index.htm
2019-06-21III PETER W. RODINODir Govt Relations/SectryBuy8,695.004.0335,040.8512,590.00https://www.sec.gov/Archives/edgar/data/946644/000170262619000004/0001702626-19-000004-index.htm
2019-11-29THOMAS K. EQUELSExec.Vice Chairman/CEO/Pres.Buy19,531.000.407,812.40128,289.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000023/0001450324-19-000023-index.htm
2019-06-21THOMAS K. EQUELSExec. Vice Chairman/CEO/Pres.Buy29,404.004.03118,498.121,393,611.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000011/0001450324-19-000011-index.htm
2019-11-29ELLEN M LINTALCFOBuy5,208.000.402,083.2014,172.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000025/0001450324-19-000025-index.htm
2019-12-13THOMAS K. EQUELSExec.Vice Chairman/CEO/Pres.Buy17,960.000.447,812.60146,249.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000028/0001450324-19-000028-index.htm
2019-12-31THOMAS K. EQUELSExec.Vice Chairman/CEO/Pres.Buy14,741.000.537,812.73160,990.00https://www.sec.gov/Archives/edgar/data/946644/000145032420000001/0001450324-20-000001-index.htm
2020-08-21THOMAS K. EQUELSCEOBuy10,730.002.3325,000.90171,717.00https://www.sec.gov/Archives/edgar/data/946644/000145032420000005/0001450324-20-000005-index.htm
2020-09-03THOMAS K. EQUELSCEO & PresidentBuy12,316.002.0325,001.48184,033.00https://www.sec.gov/Archives/edgar/data/946644/000145032420000006/0001450324-20-000006-index.htm
2019-10-15III PETER W. RODINODir Govt Relations/SectryBuy6,286.000.583,645.8818,866.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000014/0001450324-19-000014-index.htm
2019-12-13ELLEN M LINTALCFOBuy4,789.000.442,083.2218,961.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000030/0001450324-19-000030-index.htm
2019-06-21WILLIAM M MITCHELLDirectorBuy9,677.004.0338,998.3120,838.00https://www.sec.gov/Archives/edgar/data/946644/000119143419000004/0001191434-19-000004-index.htm
2019-12-31ELLEN M LINTALCFOBuy3,931.000.532,083.4322,892.00https://www.sec.gov/Archives/edgar/data/946644/000145032420000003/0001450324-20-000003-index.htm
2019-10-31III PETER W. RODINODir Govt Relations/SectryBuy7,297.000.503,648.5026,163.00https://www.sec.gov/Archives/edgar/data/946644/000158370119000006/0001583701-19-000006-index.htm
2019-06-21STEWART APPELROUTHDirectorBuy9,677.004.0338,998.3126,708.00https://www.sec.gov/Archives/edgar/data/946644/000170262619000003/0001702626-19-000003-index.htm
2019-11-15III PETER W. RODINODir Govt Relations/SectryBuy7,752.000.473,643.4433,915.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000019/0001450324-19-000019-index.htm
2019-11-29III PETER W. RODINODir Govt Relations/SectryBuy9,115.000.403,646.0043,030.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000024/0001450324-19-000024-index.htm
2019-10-31ELLEN M LINTALCFOBuy4,167.000.502,083.504,531.00https://www.sec.gov/Archives/edgar/data/946644/000158370119000007/0001583701-19-000007-index.htm
2019-12-13III PETER W. RODINODir Govt Relations/SectryBuy8,381.000.443,645.7451,411.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000029/0001450324-19-000029-index.htm
2019-06-21DAVID R STRAYERChief Science/Medical OfficerBuy2,481.004.039,998.435,420.00https://www.sec.gov/Archives/edgar/data/946644/000170262619000005/0001702626-19-000005-index.htm
2019-12-31III PETER W. RODINODir Govt Relations/SectryBuy6,879.000.533,645.8758,290.00https://www.sec.gov/Archives/edgar/data/946644/000145032420000002/0001450324-20-000002-index.htm
2019-06-27THOMAS K. EQUELSExec. Vice Chairman/CEO/Pres.Buy2,632.004.3711,501.8463,041.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000012/0001450324-19-000012-index.htm
2019-10-15THOMAS K. EQUELSExec. Vice Chairman/CEO/Pres.Buy13,470.000.587,812.6076,511.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000013/0001450324-19-000013-index.htm
2019-06-21WAYNE S SPRINGATESr. VP of OperationsBuy5,211.004.0321,000.338,672.00https://www.sec.gov/Archives/edgar/data/946644/000119143419000005/0001191434-19-000005-index.htm
2019-11-15ELLEN M LINTALCFOBuy4,433.000.472,083.518,964.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000020/0001450324-19-000020-index.htm
2019-10-31THOMAS K. EQUELSExec. Vice Chairman/CEO/Pres.Buy15,625.000.507,812.5092,136.00https://www.sec.gov/Archives/edgar/data/946644/000145032419000017/0001450324-19-000017-index.htm